Teva's Drug Development Pivot: Dr. Eric A. Hughes EVP, Global R&D and Chief Medical Officer
“The greatest opportunity at Teva is our innovative pipeline. We’re really leaning in on our innovative pipeline as an integral part of our pivot to growth strategy.”This is the ambitious vision of Dr Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva Pharmaceuticals.He speaks about the company’s strategic transformation from generics powerhouse to innovative biopharmaceutical leader - including how strategic partnerships and a matrix organisational approach are driving Teva’s remarkable 10 consecutive quarters of growth. He shares best practices on leveraging generics expertise for innovation, building successful partnerships across multiple therapeutic areas, and creating synergies between different business portfolios.Full article here
--------
17:51
--------
17:51
How Grünenthal Builds Strategic External Supply Relationships with Felipe Furiati
“We need to strive to be an easy client. Being an easy client with clear goals and internal alignment is key for successful long-term relationships with CMOs. Equally important is how we manage internally – how we align internally and bring that one message to the CMOs.”Felipe Furiati, Senior Director External Supply Operations at Grünenthal, manages external supply operations across a €2 billion portfolio whilst leading crisis management and M&A integration activities.Felipe brings a distinctive background to external manufacturing, having started as a pharmacist in QA at Johnson & Johnson, spent time in management consulting at Bain & Company, and returned to pharmaceutical operations with experience spanning both technical and strategic functions.In the latest PharmaSource podcast episode, Felipe shares practical insights on building strategic partnerships without volume leverage, implementing product-centric supply chain management, and using digital tools for supplier selection – approaches that are particularly relevant for mid-sized pharmaceutical companies navigating complex supplier networks and geopolitical uncertainty.
--------
38:03
--------
38:03
BioRN Reports Surge in US Applications as Scientists Seek New Opportunities - Interview with Dr. Julia Schaft, Managing Director
"We are seeing a doubling or tripling of applications from the United States. You can really feel that shift already. People have been offered jobs and professorships and are already here in Heidelberg."Dr. Julia Schaft, Managing Director at BioRN Cluster Management GmbH, reveals the significant increase in American scientists exploring opportunities in Germany's Rhine-Neckar biotech hub as researchers seek new environments that support their work.Julia brings over a decade of international experience, including 11 years in Australia working with human embryonic stem cells, before returning to Germany to drive innovation at the intersection of industry and academia. She also serves as spokesperson for bioDeutschland's Working Group of BioRegions.In the latest PharmaSource podcast episode, Julia explains how changing dynamics are creating new opportunities for European life science clusters and what this means for the global biotech landscape.https://pharmasource.global/content/podcast/the-heidelberg-advantage-biorn/
--------
20:16
--------
20:16
RFK Jr. Cancels $500M in mRNA Vaccine Development: US Government Abandons Pandemic Platform
HHS Secretary’s unprecedented move to terminate 22 federal mRNA contracts sends shockwaves through biotech sector and raises critical questions about U.S. pandemic preparednessThe pharmaceutical industry woke up to a fundamentally altered landscape this week as Health and Human Services Secretary Robert F. Kennedy Jr. announced the termination of $500 million in federal funding for mRNA vaccine development. The decision, which affects 22 active projects across major pharmaceutical companies including Pfizer, Moderna, and Sanofi, represents the most significant policy reversal in vaccine development funding in recent memory.In this episode, we speak to Ben Locwin Vice President at Reliant Life Sciences, about what why mRNA therapeutics are so an important - not just to vaccines but also to cancer, genetic disorders and other therapeutic areas.Read the article
--------
21:23
--------
21:23
From Lab to Patient: How Tetraneuron's Gene Therapy Approach is Tackling Alzheimer's Disease
"When you are seeing great results in your research lab, you think that everything has been done. But then when you try to humanise your drug, a new adventure starts, because the CMC process is very difficult. In my opinion, it's as difficult as demonstrating efficacy." - Mari Carmen ÁlvarezMari Carmen Álvarez PhD. is the Managing Director of Tetraneuron, a pioneering Spanish biotech developing novel gene therapies for neurodegenerative diseases. With nearly two decades in biotech leadership, she founded Valencia University's first biotech spin-off and brings expertise spanning innovation management, business development, and fundraising from seed to Series A.In the latest PharmaSource podcast episode, Mari Carmen explains why scaling gene therapy development requires more than strong science, how to navigate the complex CDMO ecosystem, and what she learned from a previous biotech failure that shaped her approach to leadership and patient impact.Full interview: https://pharmasource.global/content/podcast/from-lab-to-patient-how-tetraneurons-gene-therapy-approach-is-tackling-alzheimers-disease/
Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing.
In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides.
Make sure to subscribe for your regular dose of pharma insight.
Ireland